Conservative Treatment for Benign Prostatic Hyperplasia in Patients With Bladder Stones

Urology. 2015 Sep;86(3):450-3. doi: 10.1016/j.urology.2015.04.022. Epub 2015 Jul 30.

Abstract

Objective: To determine whether conservative management of benign prostatic hyperplasia (BPH) is an appropriate option for patients with bladder stones.

Methods: The study cohort comprised 34 men who underwent endoscopic bladder stone removal with subsequent conservative management of BPH, including watchful waiting and medical therapy (alpha-blocker ± dutasteride), between April 2006 and January 2014. We recorded BPH-related complications after stone removal and compared International Prostate Symptom Scores, quality of life scores, and postvoid residual urine volume before and after treatment. Cumulative BPH-related complication-free survival and the preoperative parameters associated with the occurrence of BPH-related complications were also analyzed.

Results: Twenty-six patients (76.5%) treated with conservative management had no BPH-related complications, during a mean follow-up of 52.6 ± 30.9 months. Mean International Prostate Symptom Scores fell from 13.5 ± 7.1 before treatment to 9.7 ± 6.3 after treatment (P = .025). One of the 34 patients (2.9%) experienced recurrent urinary infections, 2 (5.9%) had urinary retention, and 6 (17.6%) developed recurrent bladder stones. The cumulative BPH-related complication-free survival was 97.0% at 1 year, 81.8% at 3 years, and 70.5% at 5 years. Six of the men (17.6%) underwent invasive intervention for BPH after occurrence of these complications. Prostate volume was the only preoperative parameter associated with the occurrence of complications after stone removal (P = .035).

Conclusion: Conservative management of BPH can be an appropriate treatment option in men with bladder stones and concurrent mild-to-moderate lower urinary tract symptoms.

Publication types

  • Observational Study

MeSH terms

  • 5-alpha Reductase Inhibitors / therapeutic use
  • Adrenergic alpha-Antagonists / therapeutic use
  • Aged
  • Cohort Studies
  • Dutasteride / therapeutic use
  • Endoscopy*
  • Humans
  • Male
  • Middle Aged
  • Prostatic Hyperplasia / complications*
  • Prostatic Hyperplasia / therapy*
  • Quality of Life
  • Treatment Outcome
  • Urinary Bladder Calculi / complications
  • Urinary Bladder Calculi / surgery*
  • Watchful Waiting

Substances

  • 5-alpha Reductase Inhibitors
  • Adrenergic alpha-Antagonists
  • Dutasteride